| Name | Title | Contact Details |
|---|
Amedisys is a leading home health and hospice care company focused on bringing home the continuum of care. We deliver personalized home health and hospice care to thousands of patients and their families, in the comfort of their own homes. Our care teams deliver personalized home health and hospice care to approximately 380,000 patients each year. Amedisys is a post-acute care partner to more than 2,233 hospitals and 61,900 physicians across the country. We provide the care that is best for our patients, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering them to manage a chronic disease, palliative care for those with a terminal illness, or hospice care at the end of life. Amedisys is a recognized innovator, being one of the first in the industry to equip its clinicians with point-of-care laptop technology and referring physicians with an internet portal that enables real-time coordination of patient care seamlessly. Amedisys also has the industry`s first-ever nationwide Care Transitions program, designed to reduce unnecessary hospital readmissions through patient and caregiver health coaching and care coordination, which starts in the hospital and continues throughout completion of the patient`s home health plan of care.
Intrim Health Care is a Cedar Bluff, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ELPRO SERVICES is a Marietta, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.
Cofounded by Frank M. Reynolds, MIT`s Dr. Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione, PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson`s disease, and spinal cord injury.